MedTrace Logo

Prognostic Value of Anti-Ro52 Antibodies in Connective Tissue Diseases (a-Ro52)

NCT03565601 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2019-12-09

No results posted yet for this study

Summary

Anti-Ro52 autoantibodies can be detected in patients with several autoimmune diseases. Clinical significance of anti-Ro52 is controversial. The presence of anti-Ro52 may be a factor associated with disease severity (interstitial lung disease, vasculopathy) and cancers. The aim of this study is to assess interstitial lung disease and vasculopathy prevalence and severity, cancers occurence and others clinical features of connective tissue disease patients with anti-Ro52 autoantibodies.

Conditions

  • Connective Tissue Diseases

Interventions

OTHER

Follow-up

Clinical data, radiological data and laboratory tests follow-up

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    lead OTHER

Principal Investigators

  • Roland JAUSSAUD, Pr · Central Hospital, Nancy, France

  • Paul DECKER, MR · Central Hospital, Nancy, France

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2020-09-01
Completion
2020-09-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03565601 on ClinicalTrials.gov